Incidence, risk factors, and outcomes of febrile neutropenia in Thai hematologic malignancy patients receiving chemotherapy: A 6-year retrospective cohort study

7Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

A 6-year retrospective cohort study was conducted among Thai hematologic malignancy (HM) patients receiving intensive chemotherapy. Of the 145 eligible patients receiving 893 chemotherapy sessions, 46.9% were female, median age was 52 years, and the most common HM diagnosis was diffuse large B-cell lymphoma (46.2%). Febrile neutropenia (FN) occurred in 14.9% of chemotherapy sessions with an incidence of 24.8 per 1,000 chemotherapy cycles per year. Independent factors associated with FN were receiving the first chemotherapy cycle [adjusted hazard ratio (aHR) 4.1], having hemoglobin ≤100 g/L (aHR 3.7) and platelet ≤140,000/μL (aHR 2.7) on chemotherapy day and receiving acute myeloid leukemia regimens (aHR 20.8). Granulocyte colony stimulating factor was significantly associated with reduced rate of FN when given in those receiving CHOP regimen. With the median follow-up time of 16 months, the overall survival time was significantly longer in patients without FN than those with FN (61.7 vs. 20.8 months; p < 0.001).

Cite

CITATION STYLE

APA

Limvorapitak, W., & Khawcharoenporn, T. (2015). Incidence, risk factors, and outcomes of febrile neutropenia in Thai hematologic malignancy patients receiving chemotherapy: A 6-year retrospective cohort study. Asian Pacific Journal of Cancer Prevention, 16(14), 5945–5950. https://doi.org/10.7314/APJCP.2015.16.14.5945

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free